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JOURNAL OF HEPATOLOGYPNPLA3 rs738409 and ﬁbrosis progression in chronic hepatitis
C – There is more to it than just fat!
To the Editor:
The Hepatology community has seen a substantial rise in publica-
tions reporting data on genetic risk factors conferring risk to ﬁbro-
sis progression in non-alcoholic, alcoholic, and chronic hepatitis
C-related liver diseases. For long, hypothesis-driven, often sin-
gle-centre genetic case control studies have reported associations
of certain candidate genes with ﬁbrosis/cirrhosis which could not
be replicated. With genome-wide association studies (GWAS)
becoming a standard tool in translational research, novel candi-
date genes enter the stage which have been identiﬁed by system-
atic screening experiments [1]. GWAS make use of a hypothesis-
free, or rather – hypothesis-generating approach, and have the
potential to uncover genetic risk factors which had not been con-
sidered based on our previous pathophysiological understanding.
A striking example for such revelation is the gene coding for pat-
atin-like phospholipase domain containing-3 (PNPLA3; adiponu-
trin) of which a polymorphic variant (rs738409 G >C) was found
associatedwith liver fat content in a landmark GWAS [2], and sub-
sequently with progression of non-alcoholic fatty liver disease
(NAFLD) [3], and alcoholic liver disease (ALD) [4,5] by means ofJournal of Hepatology 201candidate case control studies. The role of PNPLA3 rs738409 as a
risk factor for progressive ﬁbrosis can now be extended to chronic
hepatitis C. Only in 2011, four studies presented data on the role of
PNPLA3 rs738409 G which unanimously conﬁrm that carriage of
at least one allele increases the risk of advanced ﬁbrosis and cir-
rhosis [6–9] (Table 1). Our own data indicate that this association
is particularly evident in hepatitis C virus-infected individuals
who regularly drink alcohol as opposed to abstainers [6]. Regard-
ing the latter, PNPLA3 rs738409 G appears to modulate fat storage
in the liver by a yet unknown mechanism, possibly by interaction
of PNPLA3 with viral epitopes. Indeed, from the data presented in
published studies, it becomes clear that PNPLA3 rs738409 G nei-
ther aggravates steatosis nor ﬁbrosis in patients with genotype
3, supporting the hypothesis that mostly genotype 1-speciﬁc
interactions with PNPLA3 are involved.
In this issue of the Journal, Valenti and coworkers have
undertaken a pooled analysis of our [6] and their data [7] after
stratifying their patients into ‘‘at-risk’’ drinkers (daily alcohol con-
sumptionP20 g) and abstainers [10]. Hereby, they conﬁrm that
carriage of PNPLA3 rs738409 G is a risk factor for steatosis in
abstainers, but not in at risk drinkers, possibly due to a confound-
ing effect on steatosis by concomitant alcohol consumption. In
addition, by increasing the numbers of total cases and controls,1 vol. 55 j 1467–1472 1471
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Table 1. Genetic candidate gene association studies on the role of PNPLA3 rs738409 G as a risk factor for ﬁbrosis and cirrhosis.
Author 
[Ref]
Patients (n) End points Subgroup 
analysis
Results
OR 95% CI p value
Müller et al., 
[6]
Steatosis (442)
Cirrhosis (605)
Steatosis
Cirrhosis
Abstainers
“At-risk” drinkers
Association with
steatosis in abstainers 
cirrhosis in “at-risk” drinkers 
12.61
4.77
1.48-107.7
1.39-6.38
0.021
0.013
Valenti et al.,
[7]
Two 
independent 
cohorts
(325/494)
Steatosis
Cirrhosis
HCC
Therapy response
None Association with
steatosis
therapy response
HCC
1.9
1.47
0.63
2.61
1.4-2.7
1.2-19
0.4-0.8
1.3-3.6
<0.001
0.002
0.006
0.002
Cai et al.,
 [8]
626 Steatosis Genotype 3
Genotype non-3
Association with
steatosis but only in viral 
genotype non-3
1.88 1.57-2.25 <0.001
Trepo et al., 
[9]
537 Steatosis
Fibrosis
Fibrosis progression
Therapy response
None Association with
steatosis 2.55
3.13
2.64
1.08-6.03
1.50-6.51
1.22-5.67
0.034
0.002
0.013
Letters to the Editorthey convincingly show that PNPLA3 rs738409 G is also a risk fac-
tor for cirrhosis in abstainers, with an additional increase of the
odds ratio (OR) in at risk drinkers. Of note, a subgroup analysis
of our latest data [9], conﬁrmed these observations [6,10]. Again,
only abstainers were at risk of steatosis (OR = 4.52 95% conﬁdence
interval [CI] 1.32–15.48, p = 0.016). Moreover, PNPLA3 rs738409 G
remained associated with advanced ﬁbrosis in abstainers
(OR = 2.68 95% CI 1.18–6.06, p = 0.018), but still its impact on
ﬁbrosis was stronger in ‘‘at-risk’’ drinkers (OR = 10.34 95% CI
1.15–93.16, p = 0.037). In our view, these analyses provide a per-
fect example of host-environment interactions inwhich the risk of
developing cirrhosis increases in a ‘‘dose-dependent’’ manner
with the number of risk factors present (PNPLA3 rs738409 G, hep-
atitis C virus, and alcohol).
Together, data from these four independent studies deliver
strong evidence for a signiﬁcant role of PNPLA3 rs738409 for pro-
gressive liver disease not only in NAFLD and ALD, but also in CHC.
What needs to be elucidated now is to decipher the cross-talk
between PNPLA3 (and its genetic variation) and ﬁbrosis-related
intracellular signalling. Fat accumulation may do harm in hepati-
tis C infected subjects – but as we know from NAFLD, it requires a
‘‘second hit’’ to cause inﬂammation and ﬁbrosis.
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